Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)
================================================================================================================================================

* Bilal A Siddiqui
* Brian F Chapin
* Sonali Jindal
* Fei Duan
* Sreyashi Basu
* Shalini S Yadav
* Ai-Di Gu
* Alexsandra B Espejo
* Michelle Kinder
* Curtis A Pettaway
* John F Ward
* Rebecca S S Tidwell
* Patricia Troncoso
* Paul G Corn
* Christopher J Logothetis
* Roland Knoblauch
* Natalie Hutnick
* Marco Gottardis
* Charles G Drake
* Padmanee Sharma
* Sumit K Subudhi